177 related articles for article (PubMed ID: 32739007)
1. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk.
Thomas R; Hallett PJ; Isacson O
Int Rev Neurobiol; 2020; 154():279-302. PubMed ID: 32739007
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
Volta M
Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
[TBL] [Abstract][Full Text] [Related]
3. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal impairment in Parkinson's disease.
Dehay B; Martinez-Vicente M; Caldwell GA; Caldwell KA; Yue Z; Cookson MR; Klein C; Vila M; Bezard E
Mov Disord; 2013 Jun; 28(6):725-32. PubMed ID: 23580333
[TBL] [Abstract][Full Text] [Related]
5. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.
Schindlbeck KA; Vo A; Nguyen N; Tang CC; Niethammer M; Dhawan V; Brandt V; Saunders-Pullman R; Bressman SB; Eidelberg D
Cereb Cortex; 2020 May; 30(5):2867-2878. PubMed ID: 31813991
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY; Menozzi E; Chau KY; Schapira AHV
J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's Disease-Related Genes and Lipid Alteration.
Fais M; Dore A; Galioto M; Galleri G; Crosio C; Iaccarino C
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299248
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
Usenko TS; Senkevich KA; Basharova KS; Bezrukova AI; Baydakova GV; Tyurin AA; Beletskaya MV; Kulabukhova DG; Grunina MN; Emelyanov AK; Miliukhina IV; Timofeeva AA; Zakharova EY; Pchelina SN
Gene; 2023 Oct; 882():147639. PubMed ID: 37473971
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 and the Endolysosomal System in Parkinson's Disease.
Erb ML; Moore DJ
J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease.
Cogo S; Manzoni C; Lewis PA; Greggio E
J Neurochem; 2020 Feb; 152(3):273-283. PubMed ID: 31693760
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
15. Two Methods to Analyze LRRK2 Functions Under Lysosomal Stress: The Measurements of Cathepsin Release and Lysosomal Enlargement.
Sakurai M; Kuwahara T
Methods Mol Biol; 2021; 2322():63-72. PubMed ID: 34043193
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
18. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.
Nguyen M; Wong YC; Ysselstein D; Severino A; Krainc D
Trends Neurosci; 2019 Feb; 42(2):140-149. PubMed ID: 30509690
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.
Korecka JA; Thomas R; Christensen DP; Hinrich AJ; Ferrari EJ; Levy SA; Hastings ML; Hallett PJ; Isacson O
Hum Mol Genet; 2019 Oct; 28(19):3232-3243. PubMed ID: 31261377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
